Publikationen
Aliment Pharmacol Ther. 2023 DOI: 10.1111/apt.17616
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerativecolitis: A two-yearpropensity-score-adjustedanalysis from the prospective, observational VEDOIBD-study
Bernd Bokemeyer1,2,3 | Sandra Plachta-Danielzik2| Romina di Giuseppe2 |Philipp Efken4 | Wolfgang Mohl5 | Thomas Krause6 | Martin Hoffstadt7 |Robert Ehehalt8 | Leo Trentmann9 | Axel Schweitzer10 | Petra Jessen11 |
Petra Hartmann4 | Stefan Schreiber2,3,
Inflammatory Bowel Diseases, 2023 doi.org/10.1093/ibd/izad138
Real-World Effectiveness of Vedolizumab vs Anti-TNF
in Biologic-naïve Crohn’s Disease Patients: A 2-year
Propensity-score-adjusted Analysis from the VEDOIBD-Study
Bernd Bokemeyer, MD,*,†,‡,#, Sandra Plachta-Danielzik, PhD,*,# Romina di Giuseppe, PhD,*Philipp Efken, MD,§ Wolfgang Mohl, MD,¶ Martin Hoffstadt, MD,∥ Thomas Krause, MD,**Axel Schweitzer, MD,†† Elisabeth Schnoy, MD,‡‡ Raja Atreya, MD,§§ Niels Teich, MD,¶¶,Leo Trentmann, MD,∥∥ Robert Ehehalt, MD,*** Petra Hartmann,§ and Stefan Schreiber, MD,‡
ECCO 2019
GO-CUTE: Golimumab in real world practice in patients with ulcerative colitis:
2-year interim results from a non-interventional trial in Germany
Teich N.1, Grümmer H.2, Jörgensen E.3, Liceni T.4, Holtkamp-Endemann F.5, Cornillie F.6, Hohenberger S.7, Fischer T.7
ECCO 2019
Run-CD-Studie
Effectiveness and Quality of Life (QoL) of Ustekinumab (UST) therapy in a Real World Setting in Germany – First Results of the RUN-CD Study
Bernd Bokemeyer, Minden, Sandra Plachta-Danielzik, Kiel, Niels Teich, Leipzig, Wolfgang Mohl, Saarbrücken, Martin Hoffstadt, Iserlohn, Axel Schweitzer, Münster, Manfred von der Ohe, Herne, Thomas Krause, Kassel, Jessica Höchstödter, Kiel, Petra Hartmann, Minden, Berit Wiebe, Münster, Stefan Schreiber, Kiel
« zurück